| Literature DB >> 3136966 |
H A Bird1, J Hill, N G Sitton, J S Dixon, V Wright.
Abstract
Diphosphonates reduce the rate of bone turnover. They have additional pharmacological properties improving adjuvant arthritis in rats and lowering ESR in this condition. We have evaluated etidronate disodium, a diphosphonate commonly prescribed in the United Kingdom for Paget's disease in patients with rheumatoid arthritis. Apart from an early improvement in articular index, perhaps reflecting anti-inflammatory activity, no significant change occurred in clinical variables or in laboratory indices of 'secondline' action at a dose of 5 mg/kg/day.Entities:
Mesh：
Substances：
Year: 1988 PMID： 3136966 DOI： 10.1007/bf02284063
Source DB: PubMed Journal: Clin Rheumatol ISSN： 0770-3198 Impact factor: 2.980